Neuropeptide Y-like immunoreactivity in neurons of the human retina

Cell types and cell circuits in human and non-human primate retina

This review summarizes our current knowledge of primate including human retina focusing on bipolar, amacrine and ganglion cells and their connectivity. We have two main motivations in writing. Firstly, recent progress in non-invasive imaging methods to study retinal diseases mean that better understanding of the primate retina is becoming an important goal both for basic and for clinical sciences. Secondly, genetically modified mice are increasingly used as animal models for human retinal diseases. Thus, it is important to understand to which extent the retinas of primates and rodents are comparable. We first compare cell populations in primate and rodent retinas, with emphasis on how the fovea (despite its small size) dominates the neural landscape of primate retina. We next summarise what is known, and what is not known, about the postreceptoral neurone populations in primate retina. The inventories of bipolar and ganglion cells in primates are now nearing completion, comprising ~12 types of bipolar cell and at least 17 types of ganglion cell. Primate ganglion cells show clear differences in dendritic field size across the retina, and their morphology differs clearly from that of mouse retinal ganglion cells. Compared to bipolar and ganglion cells, amacrine cells show even higher morphological diversity: they could comprise over 40 types. Many amacrine types appear conserved between primates and mice, but functions of only a few types are understood in any primate or non-primate retina. Amacrine cells appear as the final frontier for retinal research in monkeys and mice alike.

Macromolecular markers in normal human retina and applications to human retinal disease

Macromolecular cell markers are essential for the classification and characterization of the highly complex and cellularly diverse vertebrate retina. Although a plethora of markers are described in the current literature, the immunoreactivity of these markers in normal human tissue has not been fully determined. This is problematic as they are quintessential to the characterization of morphological changes associated with human retinal disease. This review provides an overview of the macromolecular markers currently available to assess human retinal cell types. We draw on immunohistochemical studies conducted in our laboratories to describe marker immunoreactivity in human retina alongside comparative descriptions in non-human tissues. Considering the growing number of eye banks services offering healthy and diseased human retinal tissue, this review provides a point of reference for future human retina studies and highlights key species specific disease applications of some macromolecular markers.

Activation of Neuropeptide Y Receptors Modulates Retinal Ganglion Cell Physiology and Exerts Neuroprotective Actions In Vitro

Neuropeptide Y (NPY) is expressed in mammalian retina but the location and potential modulatory effects of NPY receptor activation remain largely unknown. Retinal ganglion cell (RGC) death is a hallmark of several retinal degenerative diseases, particularly glaucoma. Using purified RGCs and ex vivo rat retinal preparations, we have measured RGC intracellular free calcium concentration ([Ca²⁺]_i) and RGC spiking activity, respectively. We found that NPY attenuated the increase in the [Ca²⁺]_i triggered by glutamate mainly via Y₁ receptor activation. Moreover, (Leu³¹, Pro³⁴)−NPY, a Y₁/Y₅ receptor agonist, increased the initial burst response of OFF-type RGCs, although no effect was observed on RGC spontaneous spiking activity. The Y₁ receptor activation was also able to directly modulate RGC responses by attenuating the NMDA-induced increase in RGC spiking activity. These results suggest that Y₁ receptor activation, at the level of inner or outer plexiform layers, leads to modulation of RGC receptive field properties. Using in vitro cultures of rat retinal explants exposed to NMDA, we found that NPY pretreatment prevented NMDA-induced cell death. However, in an animal model of retinal ischemia-reperfusion injury, pretreatment with NPY or (Leu³¹, Pro³⁴)−NPY was not able to prevent apoptosis or rescue RGCs. In conclusion, we found modulatory effects of NPY application that for the first time were detected at the level of RGCs. However, further studies are needed to evaluate whether NPY neuroprotective actions detected in retinal explants can be translated into animal models of retinal degenerative diseases.

Emerging novel roles of neuropeptide Y in the retina: from neuromodulation to neuroprotection

Neuropeptide Y (NPY) and NPY receptors are widely expressed in the central nervous system, including the retina. Retinal cells, in particular neurons, astrocytes, and Müller, microglial and endothelial cells express this peptide and its receptors (Y1, Y2, Y4 and/or Y5). Several studies have shown that NPY is expressed in the retina of various mammalian and non-mammalian species. However, studies analyzing the distribution of NPY receptors in the retina are still scarce. Although the physiological roles of NPY in the retina have not been completely elucidated, its early expression strongly suggests that NPY may be involved in the development of retinal circuitry. NPY inhibits the increase in [Ca(2+)]i triggered by elevated KCl in retinal neurons, protects retinal neural cells against toxic insults and induces the proliferation of retinal progenitor cells. In this review, we will focus on the roles of NPY in the retina, specifically proliferation, neuromodulation and neuroprotection. Alterations in the NPY system in the retina might contribute to the pathogenesis of retinal degenerative diseases, such as diabetic retinopathy and glaucoma, and NPY and its receptors might be viewed as potentially novel therapeutic targets.

Neuropeptides and diabetic retinopathy

Diabetic retinopathy, a common complication of diabetes, develops in 75% of patients with type 1 and 50% of patients with type 2 diabetes, progressing to legal blindness in about 5%. In the recent years, considerable efforts have been put into finding treatments for this condition. It has been discovered that peptidergic mechanisms (neuropeptides and their analogues, activating a diverse array of signal transduction pathways through their multiple receptors) are potentially important for consideration in drug development strategies. A considerable amount of knowledge has been accumulated over the last three decades on human retinal neuropeptides and those elements in the pathomechanisms of diabetic retinopathy which might be related to peptidergic signal transduction. Here, human retinal neuropeptides and their receptors are reviewed, along with the theories relevant to the pathogenesis of diabetic retinopathy both in humans and in experimental models. By collating this information, the curative potential of certain neupeptides and their analogues/antagonists can also be discussed, along with the existing clinical treatments of diabetic retinopathy. The most promising peptidergic pathways for which treatment strategies may be developed at present are stimulation of the somatostatin-related pathway and the pituitary adenylyl cyclase-activating polypeptide-related pathway or inhibition of angiotensinergic mechanisms. These approaches may result in the inhibition of vascular endothelial growth factor production and neuronal apoptosis; therefore, both the optical quality of the image and the processing capability of the neural circuit in the retina may be saved.

Neuropeptide Y stimulates retinal neural cell proliferation--involvement of nitric oxide

Neuropeptide Y (NPY) is a 36 amino acid peptide widely present in the CNS, including the retina. Previous studies have demonstrated that NPY promotes cell proliferation of rat post-natal hippocampal and olfactory epithelium precursor cells. The aim of this work was to investigate the role of NPY on cell proliferation of rat retinal neural cells. For this purpose, primary retinal cell cultures expressing NPY, and NPY Y(1), Y(2), Y(4) and Y(5) receptors [Alvaro et al., (2007) Neurochem. Int., 50, 757] were used. NPY (10-1000 nM) stimulated cell proliferation through the activation of NPY Y(1), Y(2) and Y(5) receptors. NPY also increased the number of proliferating neuronal progenitor cells (BrdU(+)/nestin(+) cells). The intracellular mechanisms coupled to NPY receptors activation that mediate the increase in cell proliferation were also investigated. The stimulatory effect of NPY on cell proliferation was reduced by L-nitroarginine-methyl-esther (L-NAME; 500 microM), a nitric oxide synthase inhibitor, 1H-[1,2,4]oxadiazolo-[4, 3-a]quinoxalin-1-one (ODQ; 20 microM), a soluble guanylyl cyclase inhibitor or U0126 (1 microM), an inhibitor of the extracellular signal-regulated kinase 1/2 (ERK 1/2). In conclusion, NPY stimulates retinal neural cell proliferation, and this effect is mediated through nitric oxide-cyclic GMP and ERK 1/2 pathways.

Neuropeptide Y inhibits [Ca2+]i changes in rat retinal neurons through NPY Y1, Y4, and Y5 receptors

Neuropeptide Y (NPY) and NPY receptors are widely distributed in the CNS, including the retina, but the role of NPY in the retina is largely unknown. The aim of this study was to investigate whether NPY modulates intracellular calcium concentration ([Ca(2+)](i)) changes in retinal neurons and identify the NPY receptors involved. As NPY decreased the [Ca(2+)](i) amplitudes evoked by 30 mM KCl in only 50% of neurons analyzed, we divided them in two populations: NPY-non-responsive neurons (Delta2/Delta1 > or = 0.80) and NPY-responsive neurons (Delta2/Delta1 < 0.80), being the Delta2/Delta1 the ratio between the amplitude of [Ca(2+)](i) increase evoked by the second (Delta2) and the first (Delta1) stimuli of KCl. The NPY Y(1)/Y(5), Y(4), and Y(5) receptor agonists (100 nM), but not the Y(2) receptor agonist (300 nM), inhibited the [Ca(2+)](i) increase induced by KCl. In addition, the inhibitory effect of NPY on evoked-[Ca(2+)](i) changes was reduced in the presence of the Y(1) or the Y(5) receptor antagonists. In conclusion, NPY inhibits KCl-evoked [Ca(2+)](i) increase in retinal neurons through the activation of NPY Y(1), Y(4), and Y(5) receptors. This effect may be viewed as a potential neuroprotective mechanism of NPY against retinal neurodegeneration.

Neuropeptide Y-evoked proliferation of retinal glial (Muller) cells

BACKGROUND

Glial cells in human retinas and in fibrocellular membranes from patients with proliferative vitreoretinopathy (PVR) have been described to upregulate their expression of Y1 receptors for neuropeptide Y (NPY) (Soler et al.: Glia 39:320, 2002). However, it is unknown whether Y1 receptor activation causes proliferation of retinal glial cells. We investigated whether NPY exerts a proliferation-stimulating effect on retinal glial cells, and compared the NPY-evoked signaling with the signaling of purinergic P2Y receptors.

METHODS

Proliferation assays using bromodeoxyuridine were carried out on primarily cultured Muller glial cells of the guinea pig, in the absence and presence of blockers of Y1 receptors, of receptor tyrosine kinases (RTKs), of mitogen-activated protein kinases (MAPKs) and of phosphatidylinositol-3 kinase (PI3K).

RESULTS

NPY exerted a biphasic effect on Muller cell proliferation. At low concentrations (0.1 ng/ml and 1 ng/ml) it decreased the proliferation rate of the cells, while at higher concentration (100 ng/ml) it increased Muller cell proliferation. The NPY-evoked proliferation was mediated by Y1 receptor stimulation and by activation of the p44/p42 MAPKs and partially of the p38 MAPK. Moreover, Y1 receptor-induced activation of PI3K as well as transactivations of the platelet-derived and the epidermal growth factor RTKs were necessary for full mitogenic effect of NPY. Y1 and P2Y receptors share partially common signal transduction pathways in Muller cells.

CONCLUSION

It is suggested that NPY may be involved in stimulation of retinal glial cell proliferation during PVR when it is released at higher amounts into the injured retina.

Y2 receptor expression and inhibition of voltage-dependent Ca2+ influx into rod bipolar cell terminals

Neuropeptide Y (NPY) is a potent inhibitory neuropeptide expressed by amacrine cells in the rat retina. NPY modulates the release of multiple neurotransmitters in mammalian retina, yet the mechanisms mediating this regulation are not well defined. To further understand the action of NPY in the retina, Y receptor coupling to voltage-dependent Ca(2+) channels was investigated using Ca(2+) imaging with fura-2 AM to measure [Ca(2+)](i) increases in rod bipolar cell terminals. Y receptor expression was studied in rat retinal tissue with reverse transcription-polymerase chain reaction (RT-PCR). NPY inhibited the depolarization-evoked Ca(2+) influx into rod bipolar cell axon terminals and caused a dose-dependent reduction and an average maximal inhibition of 72% at 1 microM, which was reversed upon washout. K(+)-evoked Ca(2+) increases were also inhibited by the selective Y2 receptor agonists, C2-NPY and NPY(13-36), at concentrations of 1 microM, but not by the selective Y1 receptor agonist, [Leu(31)Pro(34)]NPY, selective Y4 receptor agonist, rPP, or the selective Y5 receptor agonist, [d-Trp32]-NPY. Y receptor expression was determined using RT-PCR for all known Y receptor subtypes. Y2 receptor mRNA, as well as Y1, Y4, and Y5 receptor mRNAs, are present in the rat retina. Like the rod bipolar cell, other studies in central neurons have shown that the Y2 receptor is expressed predominantly as a presynaptic receptor and that it modulates transmitter release. Together, these findings suggest that NPY activates presynaptic Y2 receptors to inhibit voltage-dependent Ca(2+) influx into rod bipolar cell terminals, and establishes one mechanism by which NPY may reduce l-glutamate release from the rod bipolar cell synapse.

Localization of neuropeptide Y1 receptor immunoreactivity in the rat retina and the synaptic connectivity of Y1 immunoreactive cells

Neuropeptide Y (NPY), an inhibitory neuropeptide expressed by a moderately dense population of wide-field amacrine cells in the rat retina, acts through multiple (Y1-y6) G-protein-coupled receptors. This study determined the cellular localization of Y1 receptors and the synaptic connectivity of Y1 processes in the inner plexiform layer (IPL) of the rat retina. Specific Y1 immunoreactivity was localized to horizontal cell bodies in the distal inner nuclear layer and their processes in the outer plexiform layer. Immunoreactivity was also prominent in cell processes located in strata 2 and 4, and puncta in strata 4 and 5 of the IPL. Double-label immunohistochemical experiments with calbindin, a horizontal cell marker, confirmed Y1 immunostaining in all horizontal cells. Double-label immunohistochemical experiments, using antibodies to choline acetyltransferase and vesicular acetylcholine transporter to label cholinergic amacrine cell processes, demonstrated that Y1 immunoreactivity in strata 2 and 4 of the IPL was localized to cholinergic amacrine cell processes. Electron microscopic studies of the inner retina showed that Y1-immunostained amacrine cell processes and puncta received synaptic inputs from unlabeled amacrine cell processes (65.2%) and bipolar cell axon terminals (34.8%). Y1-immunoreactive amacrine cell processes most frequently formed synaptic outputs onto unlabeled amacrine cell processes (34.0%) and ganglion cell dendrites (54.1%). NPY immunoreactivity in the rat retina is distributed primarily to strata 1 and 5 of the IPL, and the present findings, thus, suggest that NPY acts in a paracrine manner on Y1 receptors to influence both horizontal and amacrine cells.

Y1 receptor of neuropeptide Y as a glial marker in proliferative vitreoretinopathy and diseased human retina

The Y1 receptor of neuropeptide Y (NPY) has been demonstrated in glial cells of astrocytic lineage in vitro. We have studied the immunohistochemical expression of Y1 receptors in the glia of the diseased human retina, in tissue samples obtained after surgery for proliferative vitreoretinopathy. In this condition, glia and other cell types migrate and form epi- or subretinal membranes. Both diseased retinas (n = 8) and PVR membranes (n = 43) contained numerous Y1-immunoreactive cells. In the diseased retina, the Y1 antiserum labeled cells with the morphological radial pattern characteristic of Müller cells, whereas in the membranes, label appeared in a large population of elongate cells, measuring up to 250 microm. In both retina and membranes, double labeling demonstrated that the vast majority of Y1-immunoreactive cells were also labeled by a glial fibrillary acidic protein (GFAP) antibody, indicating their glial origin. Retinal regions devoid of GFAP immunoreactivity also lacked the Y1 label. None of these markers was detected in Müller cells of normal retina. Y1 immunoreactivity did not co-localize with smooth muscle actin immunoreactivity, a marker of myofibroblasts. Expression of Y1 receptors would characterize reactive and proliferating glial cells of the diseased retina and could perhaps be involved in the proliferation of injured glial cells causing regrowth of PVR membranes and the consequent secondary retinal detachments.

Distribution and synaptic connectivity of neuropeptide Y-immunoreactive amacrine cells in the rat retina

Neuropeptide Y (NPY) is a potent bioactive peptide that is widely expressed in the nervous system, including the retina. Here we show that specific NPY immunoreactivity was localized to amacrine and displaced amacrine cells in the rat retina. Immunoreactive cells had a regular distribution across the retina and an overall cell density of 280 cells/mm(2) in the inner nuclear layer (INL) and 90 cells/mm(2) in the ganglion cell layer (GCL). In the INL, most immunoreactive cells were characterized by small cell bodies and fine processes that appeared to ramify primarily in stratum 1 of the inner plexiform layer (IPL). A few cells in the INL also ramified in stratum 3 of the IPL. In the GCL, small to medium immunoreactive cells appeared to ramify primarily in stratum 5 of the IPL. A few immunoreactive processes, originating from somata in the INL and processes in the IPL, ramified in the OPL. NPY-immunoreactive cells contained GABA immunoreactivity, and some amacrine cells also contained tyrosine hydroxylase immunoreactivity. NPY-immunostained processes were most frequently presynaptic to nonimmunostained amacrine and ganglion cell processes and postsynaptic to nonimmunostained amacrine cell processes and cone bipolar cell axonal terminals. These findings indicate that NPY immunoreactivity is present in two populations of amacrine cells, one located in the INL and the other in the GCL, and that these cells mainly form synaptic contacts with other amacrine cells. These observations suggest that NPY-immunoreactive cells participate in multiple circuits mediating visual information processing in the inner retina.

Characterization of neuropeptide Y-expressing cells in the mouse retina using immunohistochemical and transgenic techniques

The amacrine cells of the retina are a complex family of interneurons. They are made up of numerous subgroups, each with different morphologic and/or biochemical properties and each presumably serving a different function. In this study, we characterized one subgroup, defined by its expression of a peptide, neuropeptide Y (NPY). The cells were identified using antibodies to NPY and characterized using a transgenic mouse line that expressed the reporter enzyme, beta-galactosidase, in the NPY-immunoreactive (NPY-IR) cells. We found that NPY-IR cells were present in two layers, the inner nuclear layer (INL) and the ganglion cell layer (GCL). The cells in both layers were densely distributed, with those in the INL having a mean density of 1452 +/- 65 cells/mm(2), and those in the GCL having a mean density of 644 +/- 41 cells/mm(2). The cells in the INL extended their processes in the sublamina of the inner plexiform layer (IPL) closest to the INL/IPL border, the presumptive OFF sublamina, and the cells in the GCL extended their processes in the sublamina near the GCL/IPL border, the presumptive ON sublamina. Both populations of cells were immunoreactive to a GABA transporter and, thus, likely GABAergic. The high density of these cells suggests that they play a prominent role in IPL processing. The location of their processes suggests that one population acts in the pathway that mediates OFF responses, and the other in the pathway that mediates ON responses, and their expression of a GABA marker indicates that their actions are likely inhibitory.

Development of neuropeptide Y immunoreactive amacrine and ganglion cells in the pre- and postnatal cat retina

In the adult cat, neuropeptide Y (NPY) immunoreactivity (IR) is found within a subgroup of gamma-type ganglion cells and a large group of regularly arrayed amacrine cells. To examine the development of these two cell groups, we charted the appearance and maturation of neuropeptide Y immunoreactivity in the pre- and post-natal cat retina. Neuropeptide Y immunoreactivity is first observed at the central retina within the ganglion cell layer on embryonic day 46, and immunoreactivity within amacrine cells of the inner plexiform layer is present by E50. The number of immunoreactive profiles reaches the adult level in the amacrine population first (around P7), while the ganglion cell population shows a protracted development, with new cells being added until the third postnatal week. NPY-immunoreactive profiles in the ganglion cell layer were confirmed to be ganglion cells by retrograde labeling in both pre- and post-natal animals. Thus, neuropeptide Y-immunoreactive ganglion cells and amacrine cells attain their mature state with very different timecourses, although both cell groups initially follow a central to peripheral pattern of development. Interestingly, NPY expression within the ganglion cell population is temporally correlated with retinal synaptogenesis in the inner plexiform layer. As in the adult cat, NPY-immunoreactive ganglion cells never show a regular distribution during development, while NPY-IR amacrine cells are always distributed regularly even at the earliest ages. The prenatal presence of a regular distribution of NPY-IR amacrine cells suggests that these cells may participate in establishing the ganglion cell mosaics that appear during postnatal development.

Neuropeptide Y immunoreactivity identifies a regularly arrayed group of amacrine cells within the cat retina

Retinal amacrine cells can be divided into subgroups on the basis of morphological properties and chemical content. It is likely that these subgroups have specific connections and serve unique functional roles within the inner plexiform layer. In the present study we show that immunoreactivity to neuropeptide Y (NPY) identifies a group of amacrine cells (165,000-170,000) within the adult cat retina. This is the largest group of peptide-containing amacrine cells identified to date in the cat retina. These neurons have small cell bodies and are regularly spaced at all retinal eccentricities examined. The density of NPY-immunoreactive cells, as well as their regular spacing, suggests that these neurons form a specific subgroup of the amacrine cell class and are likely to serve a unique role in the transfer of visual information through the inner plexiform layer.

Immunohistochemical localization of neuropeptide Y and somatostatin in human fetal retina

The localization of neuropeptide Y and somatostatin in the retina of six prenatal human specimens was determined by the utilization of light microscopic immunoperoxidase and immunofluorescence methods. The age of the prenatal fetuses ranged from 15 to 40 weeks of gestation. At 15 weeks, round or pear-shaped neuropeptide Y-immunopositive cells were observed in the inner nuclear layer and somatostatin immunoreactivity was only detected in the ganglion cell layer. Positive neuropeptide Y ganglion cells were observed by 17 weeks of gestation and by 28 weeks neuropeptide Y-immunopositive cells were demonstrated in the ganglion cell layer and inner nuclear layer. At 26-28 weeks, neuropeptide Y-immunopositive cells exhibited approximately the same shape as at 15 weeks of gestation, but the appearance of one or two processes was detected extending from the somata. By 38-40 weeks of gestation, neuropeptide Y-immunopositive cells were detected in the ganglion cell layer, inner nuclear layer and an immunopositive fibrous configuration in the inner plexiform layer. During this same period (38-40 weeks), somatostatin-positive cells were located in the ganglion cell layer, inner nuclear layer and the inner segments layers. Due to the difficulty of obtaining fetal materials, the exact time of initiation in the expression of neuropeptide Y and somatostatin is presently hard to delineate; however, it is safe to state that the peptides appear early in development.

Immunohistochemical localization of tyrosine hydroxylase, substance P, neuropeptide-Y and leucine-enkephalin in developing human retinal amacrine cells

Prenatal changes in the neurotransmitter/neuromodulator profiles of tyrosine hydroxylase (for dopamine), substance P, neuropeptide Y, and leucine-enkephalin were studied in developing human retinal amacrine cells by the use of immunohistochemical techniques. Tyrosine hydroxylase was localized between 10 and 12 weeks of gestation, substance P and neuropeptide Y appeared little later around 14 weeks, and leucine-enkephalin-like immunoreactivity was observed at 16 weeks.

Neuropeptide Y immunoreactivity identifies a group of gamma-type retinal ganglion cells in the cat

Ganglion cells within the cat retina have been traditionally grouped by morphological criteria into three major classes: alpha, beta, and gamma. The gamma-type cells have been least well characterized, but the available evidence indicates that this class comprises a relatively heterogeneous population of neurons. In the present study we demonstrate that an antibody for neuropeptide Y (NPY) recognizes a subpopulation of about 2,000 gamma-type ganglion cells. The NPY-immunoreactive (IR) neurons project to the superior colliculus and to the C layers of the lateral geniculate nucleus as demonstrated by retrograde labeling with fluorescent tracers (fluorogold or rhodamine latex microspheres). Virtually all of these cells disappear following lesions of the optic nerve. The NPY-IR ganglion cells were identified as gamma cells on the basis of soma size and dendritic branching patterns. The somas of these neurons are small (8-22 microns in diameter), and each cell is characterized by sparsely branching dendritic processes, usually extending into the middle third of the inner plexiform layer, the physiologically defined ON sublamina. These neurons are distributed across the entire retina, with the highest density at the area centralis. Within local regions of the retina, however, there was no indication that the NPY-IR gamma cells are arrayed in a regular mosaic pattern. These results provide the first evidence that the gamma class of ganglion cells of the cat retina can be subdivided on the basis of immunocytochemical properties.

Somatostatin-like immunoreactivity in the pigeon visual system: developmental expression and effects of retina removal

The distribution of somatostatin (SS)-containing neurons was investigated by immunocytochemical methods in the central visual system of adult, developing, and retina-ablated pigeons. In normal adult brains, SS-positive cells and processes were present in the optic tectum, the nucleus of the basal optic root, the visual Wulst, and the ectostriatum. During development, progressive increase or decrease in the numerical density and the total number of SS-containing neurons occurred as determined by quantitative analysis. Changes in SS immunoreactivity also occurred as a consequence of unilateral and bilateral retina removal immediately after hatching, i.e. before retinofugal connections have been established. In spite of the segregation of visual inputs due to the almost completely crossed retinal projections, unilateral and bilateral deafferentation differentially affected SS-containing visual regions. In addition, different effects were observed on the relative packing density of labeled cells as compared to their total number. A possible role of retinal axons in regulating the distribution of SS immunoreactivity was suggested by its altered expression induced by retinal deafferentation. In addition, parallels with the distribution of SS immunoreactivity in the pigeon's visual system were used to suggest possible equivalence between cell populations in the avian and the mammalian brains.

A neurofilament protein antibody selectively labels a large ganglion cell type in the human retina

An antibody (SMI-32) raised against the non-phosphorylated form of the neurofilament protein triplet (NFP) revealed immunoreactivity in the soma and dendritic arborization of a group of large ganglion cells in the human retina. In addition, a population of smaller somas was also faintly labeled with this antibody in the ganglion cell layer. The completely stained cells amounted to 44,000 and were non-uniformly distributed across the retina with a peak density of 100 cells/mm2 in the retinal periphery. The soma sizes increased about two-fold and dendritic field sizes about 3-fold with retinal eccentricity. The immunoreactive dendrites branched in the vitread sublamina of the inner plexiform layer. The dendritic branching pattern of these cells indicated that they correspond to the previously described shrub cells. Antibodies against NFP and neuropeptide Y showed colocalization of these markers in all of the completely stained cells.

Distribution of neuropeptide Y, substance P, and choline acetyltransferase in the developing visual system of the pigeon and effects of unilateral retina removal

The distribution of three neuroactive substances, neuropeptide Y, substance P, and choline acetyltransferase, was studied by immunocytochemical methods in central visual regions of adult, developing, and ablated pigeon brains. In normal adult brains, neuropeptide Y-positive cells and processes were present in the nucleus pretectalis, the nucleus of the basal optic root, the nucleus of the marginal optic tract, and the visual Wulst. Substance P-positive cells and processes were found in the optic tectum and in the visual Wulst. Stained fibers and terminal-like processes, but no cells, were also observed in several visual thalamic nuclei. Choline acetyltransferase-positive cells and processes were located in the optic tectum, visual Wulst, the nucleus isthmo opticus, nucleus isthmi and certain visual thalamic nuclei. Cholinergic fibers and processes, but no cells, were present in the nucleus principalis precommissuralis, the supraoptic decussation, and the nucleus lentiformis mesencephali, pars magnocellularis. In the course of development, the distribution of immunoreactivity for all three substances was found to vary. These changes often involved either progressive increases or decreases in the density of labeled cells, neuropil and/or terminal-like profiles. Experiments with retina ablated pigeons clearly demonstrated that changes in the normal pattern of immunoreactivity distribution only occurred if the retina was removed immediately after hatching, i.e., before retinofugal connections have been established. The adult pattern of immunoreactivity for all three substances appears to be reached at about the same time that the anatomical and functional maturation of the pigeon visual system is completed. The present results suggest that this temporal correlation reflects the important role that retinal afferents play in the development of these putative peptidergic and cholinergic systems.

A distinctive soma size gradient among catecholaminergic neurones of human retinae

We have examined the soma diameters and distribution of catecholaminergic (CA) cells in human retinae, by using an antibody to tyrosine hydroxylase (TH), the rate limiting enzyme in the production of catecholamines. TH-immunoreactivity was detected in two classes of cells (CA1 and CA2 cells). CA1 cells had relatively large somata (mean diameter 14 microns) located in either the inner nuclear layer (INL) or in the ganglion cell layer and extensive dendrites spreading into the other strata of the inner plexiform layer (IPL). CA2 cells had smaller, weakly labelled somata (mean diameter 9.6 microns) located principally in the inner regions of the INL and weakly labelled dendrites extending into the IPL. The mean density of CA2 cells in the far retinal periphery was approximately 38/mm2. The number of CA1 cells averaged approximately 15,600 per retina, with a mean density of 16/mm2. The density distribution of CA1 cells closely paralleled the distribution of ganglion cells, their density peaking at the foveal rim, with an area of relatively high density extending horizontally from the macula region toward the nasal margin (along the visual streak). A distinctive gradient was detected among the soma diameters of CA1 cells: they were largest in the mid-periphery, in a visual streak-like configuration around the optic disk. This gradient of soma size among CA cells closely corresponds to the density distribution of the rod photoreceptors in human retinae.

NADPH-diaphorase neurones of human retinae have a uniform topographical distribution

We have examined the morphology and distribution of neurones that contain nicotinamide adenine dinucleotide phosphate (NADPH) diaphorase in human retinae. NADPH-diaphorase reactivity was observed in three different classes of amacrine cells (ND1, ND2, ND3 cells) and in the cone photoreceptors. ND1 cells had relatively large somata (mean, 12.3 microns) located in the inner nuclear layer (INL) and in the ganglion cell layer (GCL). Their dendrites were often strongly labeled and spread into either the middle or outer strata of the inner plexiform layer (IPL). The somata of ND2 cells were medium-sized (mean, 8.2 microns) and located in the INL and in the GCL; their dendrites were usually beaded and often spread in either the middle or outer strata of the IPL. ND3 cells had small, round somata (mean, 5.2 microns) located in either the INL or GCL, and were without labeled processes. The total number of NADPH-diaphorase cells (all classes) was estimated at 118,000, with a mean density of about 100/mm2. The most striking feature of NADPH-diaphorase cells in humans was that their distribution was relatively uniform across the retina, with no evidence of a peak in density at the foveal rim.

Neuropeptide Y- and substance P-like immunoreactive amacrine cells in the retina of the developing Xenopus laevis

The development of neuropeptide Y-like (NPY-LI) and substance P-like (SP-LI) immunoreactive neurons was studied in retinas of Xenopus laevis from young tadpole through to adult animals. In adult retina these neuropeptides are present in wide-field amacrine cells located in the inner nuclear layer and the ganglion cell layer of the retina. Retinal wholemount preparations and sectioned material showed that immunoreactive cells appeared during early larval life and NPY-LI occurred earlier than SP-LI cells. The primary dendritic branching of NPY-LI neurons appeared from early larval life whilst SP-LI was evident in dendrites from mid-larval stages. In postmetamorphic animals the numbers of immunoreactive cells increased in proportion to retinal area growth with a relatively constant cell density of about 35 cells/mm2 for SP-LI and 45 cells/mm2 for NPY-LI. The maturation of dendritic morphology of both NPY- and SP-LI amacrine cells appeared later in larval development than the appearance of immunoreactivity in cell somas. However, the sequence of expression of NPY- or SP-LI and their dendritic maturation was different for the two classes of amacrine cells. It is suggested that the maturation of dendritic fields of amacrine cells is complete just prior to metamorphosis, consistent with the postmetamorphic onset of electrophysiological features of ganglion cells attributed to amacrine cells.